We are a medical technology company dedicated to the early detection of pre-cancer and malignant tumors.









Who We Are

Vita Imaging, Inc. is a medical device company committed to developing and commercializing cutting-edge physician support systems for the screening and detection of cancer in the skin and internal organs. In partnership with leading scientists in the field, we are revolutionizing the way physicians can identify pre-cancerous and malignant lesions faster and with greater accuracy than ever before.

What is AURA™

AURA™ is an award winning, safe, non-invasive imaging and spectroscopy system based on pioneering Raman technology. Generating real-time results in less than 1.5 seconds, AURA™ is the fastest early and advanced-stage skin cancer detection device on the market. AURA™ is designed to aid physicians and healthcare professionals in the rapid screening, early detection, and accurate diagnosis of pre-malignant and malignant skin cancer.

At the recommendation of the FDA, Vita Imaging sponsored a Study in the US with the protocol name of “Raman Spectroscopy AURA for Non-Invasive Diagnosis of Skin Cancer” to supplement the extensive clinical data collected from Vancouver, British Columbia. The US Study was conducted at a clinical research site in Fremont, California and commenced in September 2023. There were 100 Patients who participated in the Study. The Study successfully concluded in January 2024 . Data from the Study were submitted to the FDA on January 17, 2024.

FDA review of Vita Imaging’s Class 3 PMA application is in progress. A decision from the FDA on AURA’s market clearance is expected by the first half of 2024.

Skin Cancer by the Numbers

Skin cancer is the most common form of cancer, and the most rapidly increasing
1 out of 3 new cancers diagnosed worldwide will be skin cancer
1 out of 5 Americans will develop skin cancer in their lifetime
Every hour, one person in the United States dies of melanoma
Between 2 and 3 million non-melanoma skin cancers occur globally each year
Survival rate of patients if the disease is detected early is 99%
Approximately 132,000 melanoma skin cancers occur globally each year
50% of people over the age of 65 in the US will be affected by skin cancer
Survival rate of patients with advanced stage melanoma skin cancer is 15%
Treatment of advanced stage melanoma costs 2200% more than early stage melanoma
Annual cost of treating skin cancer in the United States is estimated at $30 billion USD
The incidence of melanoma in children is increasing by 2 percent each year

Interested in adding AURA™ to your practice?

FDA approval for AURA™ is in progress. It is not yet available for sale in the US. Connect with us so your practice can be one of the first to access this cutting-edge technology.